Supposedly, Ariad -- barely breathing again after FDA issued restrictive labeling for its leukemia drug Inclusig that allows it at least to be sold to someone -- is in play as an acquisition candidate. Hmm! The Mail has identified GSK, Shire and Lilly as possible suitors. Really?
Why would a company wish to purchase a company whose only real asset is a drug that can basically be sold to dying people who haven't been helped by anything else? Is that a good investment? Would Lilly, who has suffered pipeline failure after pipeline failure of late, really be interested in shelling out for anothe failed product? This time from the outside the company rather than in. Shire just took a $600 M write off itself? Does it need to compound tha with another immediate poor acquisition? Does it? See FiercePharma and FierceBiotech.
Anyone buys this company may just be ready to board The Crazy Train.
Posted by Bruce Lehr Jan 23rd 2014.